ArticleJournal of cancer science & therapy2014
Metformin and Not Diabetes Influences the Survival of Resected Early Stage NSCLC Patients.
Article in Journal of cancer science & therapy, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- The Effect of Diabetes Mellitus on Prognosis of Patients with Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia · 2020Pooled it
- Diabetes mellitus and survival of non-small cell lung cancer patients after surgery: A comprehensive systematic review and meta-analysis.Thoracic cancer · 2019Pooled it
- Effect of hypoglycemic agents on survival outcomes of lung cancer patients with diabetes mellitus: A meta-analysis.Medicine · 2018 · on this mapPooled it
- Obesity-specific improvement of lung cancer outcomes and immunotherapy efficacy with metformin.Journal of the National Cancer Institute · 2025Article
- Carnitine palmitoyltransferase 1C promotes EMT-associated cisplatin resistance in non-small cell lung cancer cells.Cancer biology & medicine · 2025Article
- Obesity and lung cancer-a narrative review.Journal of thoracic disease · 2023Review
- Identification of patient characteristics associated with survival benefit from metformin treatment in patients with stage I non-small cell lung cancer.The Journal of thoracic and cardiovascular surgery · 2022Article
- [Metformin and malignant neoplasms: a possible mechanism of antitumor action and prospects for use in practice].Problemy endokrinologii · 2022Article
- Review
- Review
- Prognostic significance of preoperative haemoglobin A1c level in patients with lung adenocarcinoma.Interactive cardiovascular and thoracic surgery · 2021Article
- Metformin Potentiates the Anticancer Effect of Everolimus on Cervical Cancer In Vitro and In Vivo.Cancers · 2021Article
- Visceral Obesity Promotes Lung Cancer Progression-Toward Resolution of the Obesity Paradox in Lung Cancer.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2021Article
- Metformin use and lung cancer survival: a population-based study in Norway.British journal of cancer · 2021Article
- Metformin induces apoptosis and inhibits migration by activating the AMPK/p53 axis and suppressing PI3K/AKT signaling in human cervical cancer cells.Molecular medicine reports · 2021Article
- Metformin and Malignant Tumors: Not Over the Hill.Diabetes, metabolic syndrome and obesity : targets and therapy · 2021Review
- Long-term survival analysis of patients with non-small cell lung cancer complicated with type 2 diabetes mellitus.Thoracic cancer · 2020Article
- Impact of diabetes mellitus on postoperative outcomes in individuals with non-small-cell lung cancer: A retrospective cohort study.PloS one · 2020Article
- Body Mass Index Influences the Salutary Effects of Metformin on Survival After Lobectomy for Stage I NSCLC.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2019Article
- Impact of metformin use on survival outcomes in non-small cell lung cancer treated with platinum.Medicine · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPublished data suggest that diabetes influences survival of patients with lung cancer. The anti-cancer effect of metformin confounds this association. We sought to study the association of diabetes and metformin with survival in patients undergoing resection of stage I non-small cell lung cancer (NSCLC).
methodsPathologic stage I NSCLC patients undergoing anatomic resection from 2002 to 2011 were studied. A diagnosis of diabetes and diabetic medication use were identified through records. Univariate and multivariate analyses examined the association of diabetes and metformin usage with overall survival (OS).
results409 eligible patients were included in the analysis - excluding patients with neoadjuvant therapy, more than one lung cancer, or resection less than lobectomy. 71 (17.4%) patients were diabetics and 41 (10.0%) used metformin. With a median follow up of 44 months, univariate analysis demonstrates that diabetes had no effect on OS (P=0.75); however, metformin use was associated with improved OS (median survival not reached vs. 60 months; P=0.02). Metformin use remained an important predictor of good survival in multivariate analysis (HR=3.08; P<0.01) after adjusting for age, gender, pathologic stage, histology and smoking status.
conclusionMetformin use rather than diabetes is associated with improved long-term survival in Stage I NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.